---
schema_version: "secwatch.filing_event.v1"
accession: "0000950103-24-004017"
form_type: "8-K"
ticker: "PGEN"
cik: "0001356090"
company_name: "PRECIGEN, INC."
filed_at: "2024-03-19T23:59:59+00:00"
generated_at: "2026-06-04T13:07:31.790154+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Precigen reports FY2023 loss of $95.9M; plans BLA submission for PRGN-2012 in H2 2024

## Summary
- FY2023 revenue $6.2M, down 77% YoY; net loss $95.9M ($0.39 loss per share).
- Cash and investments $62.9M; SG&A down 16% to support cost containment.
- Plans to submit BLA for PRGN-2012 under accelerated approval in H2 2024; potential launch 2025.
- PRGN-2009 IND cleared Phase 2 in cervical cancer; interim data for PRGN-3006 and PRGN-3007 expected H2 2024.
- Recorded $10.4M goodwill impairment charge for Exemplar subsidiary.

## SEC filing metadata
- accession: 0000950103-24-004017
- form_type: 8-K
- ticker: PGEN
- cik: 0001356090
- company_name: PRECIGEN, INC.
- filed_at: 2024-03-19T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356090/000095010324004017/0000950103-24-004017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356090/000095010324004017/dp208564_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950103-24-004017
- JSON: https://secwatch.observer/filing/0000950103-24-004017.json
- Plain text: https://secwatch.observer/filing/0000950103-24-004017.txt

## Key facts
- Earnings Releases
  PRECIGEN, INC. reported financial results for the quarter and year ended December 31, 2023.
  - Period: the quarter and year ended December 31, 2023
  - Result: reported results
  source text: Attached as Exhibit 99.1 is a copy of a press release of Precigen, Inc., dated March 19, 2024, reporting its financial results for the quarter and year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1356090/000095010324004017/0000950103-24-004017-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.